Relay Therapeutics (RLAY) EBITDA (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of EBITDA data on file, last reported at -$73.5 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$73.5 million, up 3.38% year-over-year; the trailing twelve-month figure through Mar 2026 was -$272.2 million (up 18.06% YoY), and the FY2025 annual result was -$274.8 million, up 18.83% from the prior year.
• EBITDA eased to -$73.5 million in Q1 2026 per RLAY's latest filing, from -$54.6 million in the prior quarter.
• Over five years, EBITDA peaked at -$54.6 million in Q4 2025 and troughed at -$98.8 million in Q2 2023.
• A 5-year average of -$77.5 million and a median of -$79.5 million in 2022 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 58.92% in 2022 and fell as far as 66.15% in 2022.
• A 5-year view of EBITDA shows it stood at -$64.5 million in 2022, then fell by 24.44% to -$80.3 million in 2023, then rose by 1.0% to -$79.5 million in 2024, then surged by 31.26% to -$54.6 million in 2025, then tumbled by 34.42% to -$73.5 million in 2026.
• Business Quant data shows RLAY's EBITDA at -$73.5 million in Q1 2026, -$54.6 million in Q4 2025, and -$73.5 million in Q3 2025.